FEV1 (L) · patients with acute asthma
ICS showed no clear difference in FEV1 at 1 hour compared with placebo (low certainty).
1 finding from 1 review
FEV1 · patients with acute asthma
ICS showed no clear difference in FEV1 at 3 to 4 hours compared with placebo (moderate certainty).
1 finding from 1 review
Nausea and vomiting · patients with acute asthma
ICS showed no clear difference in adverse effects ‐ nausea/vomiting compared with placebo (low certainty).
1 finding from 1 review
Asthma relapse1at 20 to 24 days · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in asthma relapse1at 20 to 24 days compared with oral corticosteroid (high certainty).
1 finding from 1 review
Hospital admissions · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in hospital admission compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hoarseness at 20 to 24 days · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in hoarseness at 20 to 24 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Asthma relapse1at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in asthma relapse1at 16 to 21 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in hospital admission compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hoarseness at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in hoarseness at 16 to 21 days compared with oral corticosteroid (low certainty).
1 finding from 1 review